Press Releases
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Read the Latest
Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player
Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market
Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies
Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on…
Calidi Biotherapeutics to Present at Baird’s Global Healthcare Conference
SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc., (approved for listing on NYSE American under “CLDI”), a clinical-stage…
Calidi Biotherapeutics and City of Hope announce first patient dosed in a Phase 1 clinical trial evaluating neural stem cells engineered to carry an oncolytic virus, CLD-101, in recurrent high-grade glioma patients
FOR IMMEDIATE RELEASE July 18, 2023 LOS ANGELES & SAN DIEGO–(BUSINESS WIRE)– City of…
Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer
Financing led by Jackson Investment Group (JIG) with participation from Calidi Cure, LLC, a consortium…